November 2020: An exclusive look into COVID-19 findings the Amplity Insight’s team surfaced from their healthcare provider and patient interaction records. These records provide a proprietary level of detail, available nowhere else in the life science industry. The White Paper delves into the demographics, symptoms, comorbidities, and COVID-19 risk factors, and treatments received by patients who either had a confirmed COVID-19 diagnosis (positive or negative) or who had at least 3 symptoms consistent with COVID-19 in 2020 and provides insights on each.
The COVID pandemic has been the catalyst to change the way the pharmaceutical industry (Pharma) engages with HCPs. Partnering with large and small pharma alike, this whitepaper explores Amplity's flexible model tailored to each customer’s needs leveraging the benefits of remote and in-person promotion, optimizing the promotional mix across personal and non-personal channels, and ultimately providing relevant, timely, and credible information to HCPs.
COVID-19 has driven vast changes in what healthcare providers need and value from pharma companies, and as a result, the industry is striving to develop new ways to engage with physicians. Experts say this is just the beginning of a long journey and as the health ecosystem continues to morph, so will pharma interactions with HCPs.
Remote Engagement and Outsourcing Survey Results
Learn how we leverage our own technologies and processes to extract unique insights from unstructured Real World Data
Time to Embrace Companion Diagnostics to Accelerate Precision Medicine
